BioNTech Results Presentation Deck

2022 Financial Year Guidance COVID-19 Vaccine Revenues for FY 2022¹ Estimated BioNTech COVID-19 vaccine revenues Planned FY 2022 Expenses and Capex¹ R&D expenses SG&A expenses Capital expenditure Estimated FY 2022 Tax Assumptions BioN Tech Group estimated annual effective income tax rate 30 € 13-17 bn € 1,400 1,500 m M € 450-550 m € 450-550 m -28%² 1 Ranges reflect current base case projections and do not include potential effects caused by or driven from additional collaborations or potential M&A transactions. 2 BioNTech Group estimated annual effective income tax rate decreased from 31.6% (FY 2021) to -28% (FY 2022) due to decreasing average trade tax rates. BIONTECH

View entire presentation